BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/6/2019 8:51:28 AM | Browse: 1016 | Download: 1629
 |
Received |
|
2018-10-31 03:05 |
|
Peer-Review Started |
|
2018-10-31 03:36 |
|
To Make the First Decision |
|
2018-12-14 08:14 |
|
Return for Revision |
|
2018-12-19 03:51 |
|
Revised |
|
2018-12-20 08:12 |
|
Second Decision |
|
2018-12-29 05:07 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-12-30 02:37 |
|
Articles in Press |
|
2018-12-30 02:37 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-01-04 13:30 |
|
Typeset the Manuscript |
|
2019-03-05 02:15 |
|
Publish the Manuscript Online |
|
2019-03-06 08:51 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin and 5-fluorouracil regimens for advanced gastric cancer: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Bo Li, Lian Chen, Hong-Liang Luo, Feng-Ming Yi, Yi-Ping Wei and Wen-Xiong Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81560345 |
|
| Corresponding Author |
Wen-Xiong Zhang, MD, Attending Doctor, Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, 1 Minde Rd, Nanchang 330006, Jiangxi Province, China. zwx123dr@126.com |
| Key Words |
Gastric cancer; Chemotherapy; Docetaxel; Epirubicin; Cisplatin; 5-fluorouracil |
| Core Tip |
This study is the first meta-analysis to compare docetaxel, cisplatin, and 5-fluorouracil (DCF) and epirubicin, cisplatin, and 5-fluorouracil (ECF) regimens for advanced gastric cancer. The results showed that progression-free survival (PFS), overall survival (OS) and total adverse effects (AEs) between the DCF and ECF groups were comparable. The DCF group was significantly better in terms of ORR and DCR than the ECF group. However, the incidence rate of grade 3-4 AEs was also greater in the DCF group than that in the ECF group, especially for neutropenia and febrile neutropenia. Therefore, DCF regimen seems to be more suitable for advanced gastric cancer than the ECF regimen. |
| Publish Date |
2019-03-06 08:51 |
| Citation |
Li B, Chen L, Luo HL, Yi FM, Wei YP, Zhang WX. Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin and 5-fluorouracil regimens for advanced gastric cancer: A systematic review and meta-analysis. World J Clin Cases 2019; 7(5): 600-615 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i5/600.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i5.600 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
